Marksans Pharma logo

MARKSANS - Marksans Pharma Share Price

₹51.15 -2.7  -4.9%

Last Trade - 18/09/20

Small Cap
Market Cap £219.3m
Enterprise Value £219.1m
Revenue £126.8m
Position in Universe 506th / 3004
Unlock MARKSANS Revenue
Relative Strength (%)
1m -7.27%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
7,967 8,933 7,672 9,127 10,001 11,342 +7.3%
+43.0 -21.7 -89.7 +363.9 +94.1 +53.0
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 30 June 2020, Marksans Pharma Limited revenues increased 35% to RS3.31B. Net income increased from RS213.1M to RS493.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Finance costs decrease of 31% to RS15.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from RS0.52 to RS1.20.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for MARKSANS
Graphical History


MARKSANS Revenue Unlock MARKSANS Revenue

Net Income

MARKSANS Net Income Unlock MARKSANS Revenue

Normalised EPS

MARKSANS Normalised EPS Unlock MARKSANS Revenue

PE Ratio Range

MARKSANS PE Ratio Range Unlock MARKSANS Revenue

Dividend Yield Range

MARKSANS Dividend Yield Range Unlock MARKSANS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MARKSANS EPS Forecasts Unlock MARKSANS Revenue
Profile Summary

Marksans Pharma Limited is a pharmaceutical holding company. The Company is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations. The Company's product portfolio addresses various therapeutic segments, including Pain management, Cough and cold, Anti-diabetic, Cardiovascular system, Central nervous system, Antibiotic, Gastrointestinal, Anti-allergic and Miscellaneous. The Company undertakes research and development initiatives, and offers customer relationship management (CRM) services to global pharmaceutical companies. The Company has a manufacturing facility for the manufacture of oral solid tablets and soft gelatin capsules in Goa; a liquids/ointments/sachets manufacturing facility in Southport, the United Kingdom, and a solid oral dosages manufacturing facility in New York, the United States. It supplies products to approximately 20 countries. Its subsidiaries include Nova Pharmaceuticals Australasia Pty Ltd. and Marksans Pharma (UK) Limited.

Last Annual March 31st, 2020
Last Interim June 30th, 2020
Incorporated April 16, 1992
Public Since January 4, 2010
No. of Shareholders: n/a
No. of Employees: 728
Sector Healthcare
Industry Pharmaceuticals
Exchange National Stock Exchange of India
Shares in Issue 409,313,698
Free Float (0.0%)
Eligible for
MARKSANS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MARKSANS
Upcoming Events for MARKSANS
Tuesday 22nd September, 2020
Dividend For MARK.NS - 0.1000 INR
Friday 25th September, 2020 Estimate
Marksans Pharma Ltd Annual Shareholders Meeting
Tuesday 29th September, 2020
Marksans Pharma Ltd Annual Shareholders Meeting
Frequently Asked Questions for Marksans Pharma
What is the Marksans Pharma share price?

As of 18/09/20, shares in Marksans Pharma are trading at ₹51.15, giving the company a market capitalisation of ¬£219.3m. This share price information is delayed by 15 minutes.

How has the Marksans Pharma share price performed this year?

Shares in Marksans Pharma are currently trading at ₹51.15 and the price has moved by 0.261k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Marksans Pharma price has moved by 0.236k% over the past year.

What are the analyst and broker recommendations for Marksans Pharma?

Of the analysts with advisory recommendations for Marksans Pharma, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Marksans Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Marksans Pharma next release its financial results?

Marksans Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Marksans Pharma dividend yield?

The Marksans Pharma dividend yield is 0.2% based on the trailing twelve month period.

Does Marksans Pharma pay a dividend?

Last year, Marksans Pharma paid a total dividend of 0.1, and it currently has a trailing dividend yield of 0.2%. Looking ahead, shares in Marksans Pharma are due to go ex-dividend on 2020-09-22 and the next dividend pay date is 2020-10-08.

When does Marksans Pharma next pay dividends?

Marksans Pharma are due to go ex-dividend on 2020-09-22 and the next dividend pay date is 2020-10-08. The historic dividend yield on Marksans Pharma shares is currently 0.2%.

How do I buy Marksans Pharma shares?

To buy shares in Marksans Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Marksans Pharma?

Shares in Marksans Pharma are currently trading at ₹51.15, giving the company a market capitalisation of ¬£219.3m.

Where are Marksans Pharma shares listed? Where are Marksans Pharma shares listed?

Here are the trading details for Marksans Pharma:

Country of listing: India
Exchange: NSI
Ticker Symbol: MARKSANS
What kind of share is Marksans Pharma?

Based on an overall assessment of its quality, value and momentum, Marksans Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Marksans Pharma share price forecast 2020?

Shares in Marksans Pharma are currently priced at ₹51.15. At that level they are trading at 39.39% premium to the analyst consensus target price of 0.00.

How can I tell whether the Marksans Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Marksans Pharma. Over the past six months, the relative strength of its shares against the market has been 0.187k%. At the current price of ₹51.15, shares in Marksans Pharma are trading at 90.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Marksans Pharma PE Ratio?

The Marksans Pharma PE ratio based on its reported earnings over the past 12 months is 14.45. The shares are currently trading at ₹51.15.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Marksans Pharma?

Marksans Pharma's management team is headed by:

Mark Saldanha - CHM
Harshavardhan Panigrahi - CCO
Seetharama Buddharaju - NID
Sandra Saldanha - EDR
Digant Parikh - IND
Varddhman Jain - EDR
Meena Surana - IND
Who are the major shareholders of Marksans Pharma?

Here are the top five shareholders of Marksans Pharma based on the size of their shareholding:

Saldanha (Mark B.) Individual Investor
Percentage owned: 48.25% (197.5m shares)
Agarwal (Mukul Mahavir Prasad) Individual Investor
Percentage owned: 1.95% (8.00m shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 1.38% (5.63m shares)
DFA Emerging Markets Core Equity Portfolio Mutual Fund
Percentage owned: 0.52% (2.12m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 0.49% (2.00m shares)
Similar to MARKSANS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.